Healthcare

For a micro-cap of this size, a near-6% move is a small absolute shift in a low-priced share. Even so, the direction is notable because it comes as investors revisit Chimeric's core proposition: developing chimeric antigen receptor T-cell (CAR-T) therapies for difficult solid tumours, …

On 13 July 2026, BPH Global (ASX:BP8) shares were unchanged at A$0.001, a 0.00% move. At a fraction of a cent, the stock sits at the very bottom of the ASX price spectrum, where the minimum price increment is a large proportion of the …

That scale reflects growing interest in PYC's proposition: developing RNA-based medicines for rare inherited diseases with high unmet need, led by an eye-disease program that has already generated early human efficacy signals. Unlike the ASX's large commercial biotechnology names, PYC's value rests almost entirely …

The modest slip is characteristic of a small-cap drug developer between catalysts. Noxopharm has spent the past couple of years reshaping its portfolio, moving from its historical oncology candidate toward newer platforms in autoimmune disease and oncology. With its lead asset having recently cleared …

The softer price came days after Imugene announced a A$11.1 million capital raising and reported encouraging early data from its lead cancer-immunotherapy program. That mix captures the tension defining the Imugene story: advancing a differentiated cell-therapy platform while repeatedly returning to the market to …

The gain came as the small-cap materials innovator continued progressing its differentiated technology. Nanollose sits at the intersection of biotechnology and sustainable materials, using fermentation — a biotechnology method — to grow cellulose without trees, then converting it into textile fibre. To be precise: …

• Argenica Therapeutics shares rose12.00%toAUD 0.14.• The company has a market capitalisation of approximatelyAUD 17.98 million.• The stock remains78.95% lower over the past year, providing important context for the latest rally.• Investors continue monitoring FDA interactions and the advancement of the company's lead neuroprotective …